Predicting Phase III outcomes immediately post-discovery with 99.94% proven accuracy in subsequent prospective clinical trials.

Our Phase Advance™ technology powers complex mathematical models of disease progression in silico to accurately exact day-to-day responses at individual patient levels in future phase III trials. We predict clinical endpoints today, even for drugs that have never entered a single animal or patient.

How Phase Advance helps

3 months per 10 molecules to deliver predictions

97% of drug candidates will fail after spending billions of dollars

Most new pharmaceuticals will fail after discovery, during preclinical testing, or much later after years of work and billions of invested dollars.

$3B to develop one drug

Failure is apparent only after spending up to $2B in clinical trials, 12-15 years later. Only 1 in 6,000 molecules drive Return On Investment.

Phase Advance accurately predicts success or failure to save $2B and up to 14 years in costs

* average Phase Advance customer cost

Phase Advance can forecast Phase III clinical trial results at the discovery phase:

Optimal dose
Optimal drugs combos
Clinical trial endpoints before & after preclinical development
Clinical trial design

Ethnic/genetic population-based predictions of efficacy & toxicity rates
Lifetime model for optimal treatment start
Predicted efficacy versus market leader
Parameters to optimize in molecules

Our Clients

CRO

Intelligent clinical trial design
Ability to test genetically diverse populations
Reduce risk for volunteers

BioPHARMA

Rank which molecules to move forward
Optimize leads to change winners to losers
Predict performance vs standard of care

Investors

Identify which molecules to invest
Assist in due diligence
Predict performance vs competitors

AI DISCOVERY FIRMS

Predict performance
Rank and de-risk discovered molecules
Optimize predicted poor performers

Contact Us

Let us know how we can help you.